Research collaboration aims to expand recruitment, improve access to clinical trials
Click Here to Manage Email Alerts
K2 Medical Research has partnered with Magruder Eye Institute and RetiSpec in a research pilot to improve access to clinical trials, using AI-driven technology to prescreen eligible candidates in an eye care setting.
“This collaboration marks a significant milestone in our commitment to advancing medical research and improving the accessibility of clinical trials,” Sean Stanton, founder of K2 Medical Research, said in a company press release. “We are excited to work alongside Magruder Eye Institute and RetiSpec, combining our expertise to address the challenges in identifying and recruiting eligible candidates for clinical trials efficiently.”
According to the release, the collaboration aims to reduce time associated with recruiting eligible trial candidates by using RetiSpec’s AI technology — which is being developed to detect neurological diseases through an eye exam — as a prescreening tool at Magruder Eye Institute.
“Magruder Eye Institute has always been at the forefront of innovation in eye care,” John Lehr, MD, the institute’s president and medical director, said in the release. “The eye provides a unique window to the brain, and RetiSpec’s technology may offer us unprecedented insights into understanding what’s happening in the brain years before symptoms begin. This collaboration holds the potential to redefine how we approach Alzheimer’s research and pave the way for early detection and intervention strategies.”
Read more about
Click Here to Manage Email Alerts